RxDoctor Payments DataLook up a doctor →

Sean Mazer, MD

Clinical Cardiac Electrophysiology · Albuquerque, NMNPI 1821025545

Payments from drug & device makers

$330,544in general payments, 2019–2025

Across 765 payments — averaging $432.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$134K
  • Biosense Webster, Inc.$99K
  • Medtronic$46K
  • Abbott$42K
  • Boston Scientific$6K
  • Abiomed$762
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$201,22573%
  • Speaking & faculty fees$43,70016%
  • Travel & lodging$15,9276%
  • Food & beverage$13,3795%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$386,206
Medicare patients
2,666
Services billed
5,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban618$622,709
XareltoRivaroxaban141$161,663
EntrestoSacubitril/Valsartan29$40,786
JardianceEmpagliflozin32$37,180
Dofetilide27$22,088
Flecainide Acetate344$11,505
Repatha SureclickEvolocumab13$9,282
Metoprolol Succinate381$6,653
Spironolactone276$3,038
Losartan Potassium234$2,989
Diltiazem 24hr Er (Cd)Diltiazem Hcl107$2,510
Atorvastatin Calcium160$2,331
Carvedilol220$2,137
Rosuvastatin Calcium62$1,772
Amlodipine Besylate152$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$622,709618 claims
Johnson & JohnsonXarelto$259$161,663141 claims
NovartisEntresto$320$40,78629 claims
Boehringer IngelheimJardiance$13$37,18032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →